Generic Duexis Availability
Duexis is a brand name of famotidine/ibuprofen, approved by the FDA in the following formulation(s):
DUEXIS (famotidine; ibuprofen - tablet;oral)
-
Manufacturer: HORIZON PHARMA
Approval date: April 23, 2011
Strength(s): 26.6MG;800MG [RLD]
Has a generic version of Duexis been approved?
No. There is currently no therapeutically equivalent version of Duexis available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duexis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Stable compositions of famotidine and ibuprofen
Patent 8,067,033
Issued: November 29, 2011
Inventor(s): Xu; Jerry & Tidmarsh; George
Assignee(s): Horizon Pharma USA, Inc.
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Patent expiration dates:- July 18, 2026✓
- July 18, 2026
-
Methods and medicaments for administration of ibuprofen
Patent 8,067,451
Issued: November 29, 2011
Inventor(s): Tidmarsh; George & Golombik; Barry L. & Sharma; Puneet
Assignee(s): Horizon Pharma USA, Inc.
A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.Patent expiration dates:- July 18, 2026✓✓
- July 18, 2026
-
Stable compositions of famotidine and ibuprofen
Patent 8,309,127
Issued: November 13, 2012
Inventor(s): Xu; Jerry & Tidmarsh; George F.
Assignee(s): Horizon Pharma USA, Inc.
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Patent expiration dates:- July 18, 2026✓
- July 18, 2026
-
Stable compositions of famotidine and ibuprofen
Patent 8,318,202
Issued: November 27, 2012
Inventor(s): Xu; Jerry & Tidmarsh; George F.
Assignee(s): Horizon Pharma USA, Inc.
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Patent expiration dates:- July 18, 2026✓
- July 18, 2026
-
Stable compositions of famotidine and ibuprofen
Patent 8,449,910
Issued: May 28, 2013
Assignee(s): Horizon Pharma USA, Inc.
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Patent expiration dates:- July 18, 2026✓
- July 18, 2026
-
Stable compositions of famotidine and ibuprofen
Patent 8,501,228
Issued: August 6, 2013
Assignee(s): Horizon Pharma USA, Inc.
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.Patent expiration dates:- July 18, 2026✓
- July 18, 2026
More about Duexis (famotidine / ibuprofen)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 14 Reviews – Add your own review/rating
- Drug class: nonsteroidal anti-inflammatory agents
Consumer resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
